ADVANCED/METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)
Clinical trials for ADVANCED/METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) explained in plain language.
Never miss a new study
Get alerted when new ADVANCED/METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) trials appear
Sign up with your email to follow new studies for ADVANCED/METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill takes on chemo for rare lung cancer
Disease control OngoingThis phase 3 trial compares a new oral targeted drug, TAK-788 (mobocertinib), against standard chemotherapy as a first treatment for advanced non-small cell lung cancer with a specific EGFR mutation (exon 20 insertion). About 354 adults with this rare mutation will be randomly as…
Matched conditions: ADVANCED/METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New drug combo aims to extend life in advanced lung cancer
Disease control OngoingThis phase 3 trial tests whether adding eftilagimod alfa to standard immunotherapy (pembrolizumab) and chemotherapy helps people with advanced non-small cell lung cancer live longer or keep their cancer from growing. About 756 adults who have not had prior treatment for their adv…
Matched conditions: ADVANCED/METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE3 • Sponsor: Immutep S.A.S. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC